<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084404</url>
  </required_header>
  <id_info>
    <org_study_id>YCU-21001</org_study_id>
    <nct_id>NCT05084404</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Phase II Physician-initiated Clinical Trial Investigating the Efficacy and Safety of Guanabenz Acetate for Non-alcoholic Fatty Liver Disease Associated With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yokohama City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yokohama City University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8&#xD;
      mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver&#xD;
      disease/non-alcoholic steatohepatitis (NAFLD/NASH patients) with hypertension&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of those where the liver fat content (%) measured by MRI-PDFF at 16 weeks decreased by ≥ 3.46% from baseline (%)</measure>
    <time_frame>Week 16</time_frame>
    <description>MRI-PDFF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of those where the liver fat content (%) measured by MRI-PDFF at 16 weeks decreased by 3.46% or more from baseline for 4 mg group and 8 mg group (%)</measure>
    <time_frame>Week 16</time_frame>
    <description>MRI-PDFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change in liver fat content measured by MRI-PDFF</measure>
    <time_frame>Week 16</time_frame>
    <description>MRI-PDFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in ALT</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in AST</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in gamma-glutamyl transferase (γ-GTP)</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in weight</measure>
    <time_frame>Week 16</time_frame>
    <description>Body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in blood lipids</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum. Blood lipids defined as (chylomicron cholesterol, chylomicron triglyceride, lipoprotein cholesterol, low-density lipoprotein [LDL] triglyceride, very low-density lipoprotein [VLDL] cholesterol, VLDL triglyceride, free cholesterol, apoprotein A1, apoprotein B, adipsin, free fatty acid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in insulin resistance (HOMA-IR)</measure>
    <time_frame>Week 16</time_frame>
    <description>Blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in liver stiffness</measure>
    <time_frame>Week 16</time_frame>
    <description>MR elastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in fibrosis markers (enhanced liver fibrosis [ELF] score)</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in fibrosis markers (enhanced liver fibrosis Fibrosis-4 [FIB-4])</measure>
    <time_frame>Week 16</time_frame>
    <description>Serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence rate of adverse events</measure>
    <time_frame>Week 0-16</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Nonalcoholic Fatty Liver</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>4 mg/day of WY-8678 (guanabenz acetate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg/day of WY-8678 (guanabenz acetate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: 4 mg/day of WY-8678 (guanabenz acetate)</intervention_name>
    <description>Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks</description>
    <arm_group_label>4 mg/day of WY-8678 (guanabenz acetate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: 8 mg/day of WY-8678 (guanabenz acetate)</intervention_name>
    <description>Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks</description>
    <arm_group_label>8 mg/day of WY-8678 (guanabenz acetate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have received a full explanation about this study and who have provided&#xD;
             written consent.&#xD;
&#xD;
          2. Patients ≥ 20 years of age ≤ 75 years of age at the time consent was provided.&#xD;
&#xD;
          3. Patients diagnosed with essential hypertension and whose systolic blood pressure at&#xD;
             the time of screening is ≥ 130 mmHg and/or diastolic blood pressure is ≥ 85 mmHg&#xD;
             (according to the diagnostic criteria for metabolic syndrome)&#xD;
&#xD;
          4. Patients diagnosed with NAFLD/NASH who meet the following criteria (1) or (2) (1)&#xD;
             Patients diagnosed with NAFLD who meet the following three criteria: ・Diagnostic&#xD;
             imaging or histological evidence of fatty liver, ・Alcohol intake &lt; 30 g/day for men&#xD;
             and &lt; 20 g/day for women for 12 or more consecutive weeks one year before screening,&#xD;
             ・Absence of other factors that cause fattening or chronic liver disease. (2) Patients&#xD;
             with a definitive diagnosis of NASH by biopsy within 32 weeks before screening * The&#xD;
             definitive diagnostic criteria for NASH are defined as a fibrosis stage in liver&#xD;
             biopsy in the evaluation using the &quot;NASH Clinical Research Network (CRN) criteria&quot; by&#xD;
             an F1-F3 pathologist and a NAFLD activity score (NAS) ≥4 points (each item has one or&#xD;
             more points): ・Steatosis (0-3 points)&#xD;
&#xD;
               -  Ballooning (0-2 points)&#xD;
&#xD;
               -  Inflammation in the lobules (0-3 points)&#xD;
&#xD;
          5. Patients with magnetic resonance imaging (MRI)-proton density fat fraction (PDFF)&#xD;
             liver fat mass ≥ 8% at screening.&#xD;
&#xD;
          6. Patients with magnetic resonance elastography (MRE) value ≤ 3.6 kPa at screening.&#xD;
&#xD;
          7. Patients with a body mass index (BMI) ≥ 25 kg/m2 at the time of screening.&#xD;
&#xD;
          8. Patients receiving diet or exercise therapy 12 weeks before screening, with no&#xD;
             improvement.&#xD;
&#xD;
          9. Patients who are willing to maintain a stable diet and physical activity during the&#xD;
             clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, lactating, potentially pregnant women, or patients who do not agree to&#xD;
             contraception during the trial period.&#xD;
&#xD;
          2. Patients who have taken guanabenz acetate within 16 weeks prior to screening or who&#xD;
             have participated in other clinical studies (observational studies are excluded).&#xD;
&#xD;
        3. Patients with drug allergies to guanabenz acetate. 4. Patients with liver failure or&#xD;
        cirrhosis. 5. Patients with the following laboratory test values:&#xD;
&#xD;
        (1) Alanine aminotransferase (ALT) &gt; 430 IU/L (males) or &gt; 240 IU/L (female); or aspartate&#xD;
        aminotransferase (AST) &gt; 300 IU/L (males and females) (2) Prothrombin time-international&#xD;
        normalized ratio (PT-INR) ≥ 1.5 (excluding anticoagulant therapy) (3) Total bilirubin value&#xD;
        &gt; 2.0 mg/dL (excluding definitive diagnosis of Gilbert syndrome) (4) Platelet count &lt;&#xD;
        80,000/μL (5) Estimated glomerular filtration ratio (eGFR) &lt; 45 (calculated by body surface&#xD;
        area correction: standardized eGFR) 6. Patients with a history of acute or chronic liver&#xD;
        disease other than NAFLD/NASH and complications:&#xD;
&#xD;
          1. Patients suffering from hepatitis B (defined by hepatitis B surface (HBs) antigen&#xD;
             positive at the time of screening) or hepatitis C (defined by hepatitis C virus (HCV)&#xD;
             antibody positive at the time of screening). However, anti-HCV antibody positive&#xD;
             patients who are judged to be negative for hepatitis C virus ribonucleic acid&#xD;
             (HCV-RNA) can be registered if they can be confirmed to be negative for at least one&#xD;
             year before screening.&#xD;
&#xD;
          2. Patients with autoimmune hepatitis.&#xD;
&#xD;
          3. Patients with primary biliary cholangitis, primary sclerosing cholangitis, Wilson's&#xD;
             disease, α1-antitrypsin deficiency, hemochromatosis or iron overload, drug-induced or&#xD;
             alcoholic liver disease, or a history of known biliary atresia.&#xD;
&#xD;
          4. Patients with suspicion or definitive diagnosis of hepatocellular carcinoma. 7.&#xD;
             Patients with a history of human immunodeficiency virus (HIV) infection. 8. Patients&#xD;
             with findings of portal hypertension (complications: ascites, hepatic encephalopathy,&#xD;
             varicose veins, splenomegaly).&#xD;
&#xD;
        9. Patients with a history of NAFLD-related drugs (amiodarone, methotrexate, systemic&#xD;
        glucocorticoids, tetracycline, tamoxifen, higher doses of estrogen, anabolic steroids or&#xD;
        valproic acid than used for hormone replacement) or other hepatotoxins for at least 4 weeks&#xD;
        prior to screening.&#xD;
&#xD;
        10. Patients who have used the following drugs:&#xD;
&#xD;
          1. Patients who used insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, SGLT2&#xD;
             inhibitors, or thiazolidine 12 weeks before screening,&#xD;
&#xD;
          2. Patients who used ursodeoxycholic acid or vitamin E 12 weeks before screening,&#xD;
&#xD;
          3. Patients whose doses of dyslipidemia drugs or antihypertensive drugs were changed 12&#xD;
             weeks before screening,&#xD;
&#xD;
          4. Patients whose dose of oral diabetes treatment drug (dipeptidyl peptidase 4 [DPP-4]&#xD;
             inhibitor, sulfonylurea [SU] preparation, α-glucosidase inhibitor, metformin) was&#xD;
             changed 12 weeks before screening,&#xD;
&#xD;
          5. Patients who used drugs known to have a significant effect on body weight (including&#xD;
             over-the-counter drugs for weight loss) 12 weeks before screening,&#xD;
&#xD;
          6. Patients using central nervous system depressants (barbital, sodium thiopental,&#xD;
             morphine hydrochloride hydrate, brotizolam, diazepam, etc.).&#xD;
&#xD;
        11. Patients with 10% weight change 24 weeks before screening. 12. Patients scheduled to&#xD;
        undergo surgery after obesity surgery (such as gastroplasty and Roux-en-Y gastric bypass&#xD;
        surgery) or during the trial period.&#xD;
&#xD;
        13. Patients with a history of type 1 diabetes. 14. Patients with hemoglobin A1c (HbA1c) &gt;&#xD;
        9.5% at screening or with uncontrolled type 2 diabetes.&#xD;
&#xD;
        15. Patients with hyperthyroidism or hypothyroidism, or screening results showing thyroid&#xD;
        dysfunction. However, for hypothyroidism, registration is possible if thyroid replacement&#xD;
        therapy is received 12 weeks before screening and the test values are stable.&#xD;
&#xD;
        16. Patients with a history of New York heart association functional classification (NYHA&#xD;
        classification) class III or IV heart failure due to factors other than hypertension.&#xD;
&#xD;
        17. Patients with a history of myocardial infarction, unstable angina, percutaneous&#xD;
        coronary intervention, coronary artery bypass grafting, or stroke or major surgery 24 weeks&#xD;
        before screening.&#xD;
&#xD;
        18. Patients with a history of substance abuse. 19. Patients with malignant tumors.&#xD;
        However, patients who have undergone radical surgery, patients who have completed&#xD;
        chemotherapy/radiation therapy, and patients who are undergoing hormone therapy can be&#xD;
        registered.&#xD;
&#xD;
        20. Patients with known intolerance to MRI or patients who are contraindicated for MRI&#xD;
        examination.&#xD;
&#xD;
        21. Other patients who the principal investigator or sub-investigator deems inappropriate&#xD;
        for conducting this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Takaomi Kessoku, M.D., PhD.</last_name>
    <phone>+81-45-787-2800</phone>
    <phone_ext>2640</phone_ext>
    <email>takaomi0027@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Atsushi Nakajima, M.D., PhD.</last_name>
    <phone>+81-45-787-2800</phone>
    <phone_ext>2640</phone_ext>
    <email>nakajima-tky@umin.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yokohama City University</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takaomi Kessoku, MD., PhD.</last_name>
      <phone>+81-45-787-2800</phone>
      <phone_ext>2640</phone_ext>
      <email>kessoku-tho@umin.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonalcoholic Fatty Liver</keyword>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <keyword>Guanabenz</keyword>
  <keyword>Phase 2 trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanabenz</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

